 |
|
Equivalent Therapeutic Efficacy and Safety of Ivermectin and Lindane in the Treatment of Human Scabies
Edgardo N. Chouela, MD;
Alejandra M. Abeldaño, MD;
Graciela Pellerano, MD;
Marta La Forgia, MD;
Rosa María Papale, MD;
Armando Garsd, PhD;
María del Carmen Balian, MD;
Viviana Battista, MD;
Nora Poggio, MD
Arch Dermatol. 1999;135:651-655.
Objective To compare the therapeutic efficacy and safety of ivermectin and lindane for the treatment of human scabies.
Design Randomized, prospective, controlled, double-blind, "double-dummy," and parallel clinical study.
Setting A single department of dermatology at a hospital in Buenos Aires, Argentina.
Patients Patients were outpatients, hospitalized patients, and those referred to our hospital from nursing homes and asylums. Fifty-three patients had clinical signs and symptoms compatible with scabies.
Intervention Patients received either a single oral dose of ivermectin (150-200 µg/kg of body weight) or a topical application of 1% lindane solution. Treatment was repeated after 15 days if clinical cure had not occurred.
Main Outcome Measures Clinical healing and adverse effects.
Results Of 53 patients, 43 (81%) completed the study, 19 in the group treated with ivermectin and 24 in the group treated with lindane. At day 15, 14 patients (74%; 95% confidence interval, 48.8%-90.8%) in the group receiving ivermectin showed healing of their scabies and 13 patients (54%; 95% confidence interval, 32.8%-74.4%) in the group treated with lindane were healed. At 29 days, both treatments resulted in statistically equivalent therapeutic efficacy: 18 patients (95%; 95% confidence interval, 74.0%-99.9%) were healed with ivermectin and 23 patients (96%; 95% confidence interval, 78.9%, 99.9%) were healed with lindane (P<.02). Adverse effects from the treatments were few, mild, and transient. Results from laboratory tests showed no major abnormalities and no difference between treatments.
Conclusions Ivermectin is as effective as lindane for the treatment of scabies. Ivermectin is simpler to use and, therefore, is a promising tool to improve compliance and to control infestations.
From the Department of Dermatology, the Hospital General de Agudos Dr Cosme Argerich, Buenos Aires, Argentina.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLES
Ivermectin: A New Therapeutic Weapon in Dermatology?
Pascal del Giudice and Pierre Marty
Arch Dermatol. 1999;135(6):705-706.
EXTRACT
| FULL TEXT
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(6):737-738.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical practices. Scabies.
Chosidow
NEJM 2006;354:1718-1727.
FULL TEXT
Ivermectin for the Treatment of Resistant Scabies
Cook and Romanelli
The Annals of Pharmacotherapy 2003;37:279-281.
ABSTRACT
| FULL TEXT
Update in Dermatology
Kazin et al.
ANN INTERN MED 2001;135:124-132.
FULL TEXT
A Systematic Review of the Treatment of Scabies
Bigby
Arch Dermatol 2000;136:387-389.
FULL TEXT
Ivermectin: A Few Caveats Are Warranted Before Initiating Therapy for Scabies
Burkhart and Burkhart
Arch Dermatol 1999;135:1549-1550.
FULL TEXT
Ivermectin for Scabies
Altman
Arch Dermatol 1999;135:1550-1550.
FULL TEXT
Oral Ivermectin for Scabies?
JWatch General 1999;1999:4-4.
FULL TEXT
Oral Ivermectin vs. Lindane for Treating Scabies
Journal Watch Dermatology 1999;1999:4-4.
FULL TEXT
Ivermectin: A New Therapeutic Weapon in Dermatology?
del Giudice and Marty
Arch Dermatol 1999;135:705-706.
FULL TEXT
|
